Liminatus Pharma, Inc. Gains 41.27%
Wed, Jan 07, 2026 at 07:23 PM
Liminatus Pharma, Inc. (LIMN:NASDAQ) rocketted at $0.94, a gain of 41.3%. On Wed, Jan 07, 2026, LIMN:NASDAQ hit a New 2-Week High of $0.94. From Fri, Dec 26, 2025, the stock recorded 57.14% Up Days and 50.00% Green Days
The stock spiked on Thu, Oct 30, 2025 at $1.7 with a volume of 1M+.
About Liminatus Pharma, Inc. (LIMN:NASDAQ)
Liminatus Pharma, Inc. is pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies.
Top 10 Gainers:
- SMX (Security Matters) Public Limited Company (SMX:NASDAQ), 76.14%
- Regencell Bioscience Holdings Limited (RGC:NASDAQ), 60.1%
- Nuvve Holding Corp. (NVVE:NASDAQ), 59.55%
- Innovative Eyewear, Inc. (LUCY:NASDAQ), 47.46%
- Monte Rosa Therapeutics, Inc. (GLUE:NASDAQ), 45.41%
- Century Therapeutics, Inc. (IPSC:NASDAQ), 44.44%
- NovaBay Pharmaceuticals, Inc. (NBY:NYSEMKT), 43.98%
- Erasca, Inc. (ERAS:NASDAQ), 42.42%
- Momentus Inc. (MNTS:NASDAQ), 41.4%
- Liminatus Pharma, Inc. (LIMN:NASDAQ), 41.27%